A Phase 4 interventional study of Placebo and Tadalafil in Erectile Dysfunction, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-08-24.
Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies testing tadalafil in Erectile Dysfunction — 9 open to participants now, 9 under way, 3 of them phase 3. Tadalafil · Erectile Dysfunction.
Among the 57 studies testing tadalafil in Erectile Dysfunction, this one is the 17th largest by enrollment of the 56 interventional ones that give a count, is one of 5 that started in 2009, is one of 26 in phase 4, and was the 22nd registered.
702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.
Browse Erectile Dysfunction studies →9 of the 57 studies testing tadalafil in Erectile Dysfunction are open now, in 4 countries. Recruiting first, the newest first:
Surgical Outcomes Research Centre (SOuRCe) · Sites in Australia
Ages 18+ · Men only
Al-Azhar University · Sites in Egypt
Ages 18–70 · Men only
Beni-Suef University · Sites in Egypt
Ages 30–70 · Men only
Mansoura University · Sites in Egypt
Ages 21+ · Men only
Aswan University Hospital · Sites in Egypt
Ages 21+ · Men only
By country, each count listing its studies:
Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 21 · Phase 4 26
First in 2002; this study’s year is marked. 5 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 372 is above the median of 70 across 551 interventional studies indexed under Erectile Dysfunction.
Median enrollment 199 across the 56 interventional studies. Of the 42 that completed or were terminated, 13 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 57 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
28 studies in Erectile Dysfunction by Eli Lilly and Company: none open now, none under way, none of them phase 3. Of 28 finished, 14 (50%) have results posted.
Among the 28 studies in Erectile Dysfunction by Eli Lilly and Company, this one is the 15th largest by enrollment, is one of 4 that started in 2009, is one of 12 in phase 4, and was the 17th registered.
Eli Lilly and Company’s Erectile Dysfunction studies by the year they started, since 2002.
3 of the studies testing tadalafil in Erectile Dysfunction that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07642505Beni-Suef UniversityL-Citrulline and Tadalafil for Mild to Moderate Erectile Dysfunction | 2026-11 |
| NCT07391579Mansoura UniversityDaily Tadalafil 5 mg Combined With On-Demand Sildenafil 100 mg for Treatment of Erectile Dysfunction in PDE-5I Non Responder Patients | 2026-12 |
| NCT07753720Al-Azhar UniversityDaily Tadalafil as Adjunctive Therapy Versus Monotherapy for PDE5 Inhibitor-Resistant Erectile Dysfunction | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 57 studies testing tadalafil in Erectile Dysfunction, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 28 in Erectile Dysfunction:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the day of onset of efficacy of tadalafil dosed once-a-day.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Partner Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
No drug during baseline period, 2.5 mg for 14 days, then will continue at 5 mg for 14 days.
Drug: Tadalafil
No drug during baseline period, 5 mg for 14 days, then will continue at 5 mg for 14 days.
Drug: Tadalafil
No drug during baseline period, placebo for 14 days, then will continue tadalafil at 5 mg for 14 days.
Drug: Placebo · Drug: Tadalafil
One tablet orally daily
Orally once daily
Also known as: Cialis, LY450190
Earliest Onset Day Measured by Cumulative Percentage of Participants With Yes Response to Sexual Encounter Profile Diary Question 3
Cumulative percentage of participants achieving successful intercourse, as measured by "yes" responses to Sexual Encounter Profile diary question 3 (SEP3). SEP3 asks if the participant's erection lasted long enough to have successful intercourse.
Time frame: 4 days during double-blind period
Sexual Encounter Profile Diary Question Number 1, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses
Assessed was the mean change from baseline in the percentage of "yes" responses to the Sexual Encounter Profile Diary question number 1: "Were you able to achieve at least some erection (some enlargement of the penis)"? Data are presented as the mean percentage of participants who answered "yes".
Time frame: Baseline and 14 days double-blind period
Sexual Encounter Profile Diary Question Number 2, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses
Assessed was the mean change from baseline in the percentage of "yes" responses to the Sexual Encounter Profile Diary question number 2: "Were you able insert your penis into your partner's vagina?" Data are presented as the mean percentage of participants who answered yes.
Time frame: Baseline and 14 days double-blind period
Sexual Encounter Profile Diary Question Number 3, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses
Assessed was the mean change from baseline in the percentage of "yes" responses to the Sexual Encounter Profile Diary question number 3: "Did your erection last long enough for you to have successful intercourse?" Data are presented as the mean percentage of participants who answered "yes".
Time frame: Baseline and 14 days double-blind period
Sexual Encounter Profile Diary Question Number 4, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses
Assessed was the mean change from baseline in the percentage of "yes" responses to the Sexual Encounter Profile Diary question number 4: "Were you satisfied with the hardness of your erection?" Data are presented as the mean percentage of participants who answered "yes".
Time frame: Baseline and 14 days double-blind period
Sexual Encounter Profile Diary Question Number 5, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses
Assessed was the mean change from baseline in the percentage of "yes" responses to the Sexual Encounter Profile Diary question number 5: "Were you satisfied overall with this sexual experience?" Data are presented as the mean percentage of participants who answered "yes".
Time frame: Baseline and 14 days double-blind period
Sexual Encounter Profile Diary Question 3, the Overall Distribution of Time to Onset by Yes Responses
Assessed was the median time to onset of efficacy (day when 50% of participants have had at least 1 successful intercourse attempt) within the first 4 days of therapy based on a "yes" response to the sexual encounter profile diary question 3: "Did your erection last long enough for you to have successful intercourse?" Data are based on participants who responded "yes". For the placebo group, onset of efficacy was not reached within the first 4 days of therapy, therefore, the analysis timeframe was expanded for this group to determine the median time to onset of efficacy.
Time frame: 4 days double-blind period
Sexual Encounter Profile Diary Question 3, Daily Cumulative Percentage of Successful Intercourse Attempts
Assessed was the cumulative precentage of successful intercourse attempts (successful attempts relative to the total number of intercourse attempts) over the 14-day double-blind treatment period. A successful attempt was defined by a "yes" response to the sexual encounter profile diary question #3: "Did your erection last long enough for you to have successful intercourse?" Data are presented as the proportion of intercourse attempts for which participants answered "yes" relative to the total number of intercourse attempts. Total number of attempts = TNA.
Time frame: 14 days during double-blind period
Sexual Encounter Profile Diary Question 3, Percentages of Yes Responses During the Double-blind and Open-label Periods for Participants Who Were Assigned to Placebo in the Double-blind Treatment Period
Assessed were percentages of successful intercourse attempts relative to the total number of intercourse attempts over the 14-day open-label treatment period compared with the 14-day double-blind treatment period by dose group during the double-blind treatment period. A successful attempt was defined by a "yes" response to the sexual encounter profile diary question #3: "Did your erection last long enough for you to have successful intercourse?"
Time frame: 14 days double-blind and 14 days open-label
Sexual Encounter Profile Diary Question 3, Percentages of Yes Responses in the Double-blind Period and the Open-label Period for Participants Who Were Assigned to Tadalafil 2.5 mg in the Double-blind Treatment Period
Assessed were percentages of successful intercourse attempts relative to the total number of intercourse attempts over the 14-day open-label treatment period compared with the 14-day double-blind treatment period by dose group during the double-blind treatment period. A successful attempt was defined by a "yes" response to the sexual encounter profile diary question #3: "Did your erection last long enough for you to have successful intercourse?"
Time frame: 14-day double-blind and 14-day open-label
Sexual Encounter Profile Diary Question 3, Percentages of Yes Responses in the Double-blind Period and the Open-label Period for Participants Who Were Assigned to Tadalafil 5 mg in the Double-blind Treatment Period
Assessed were percentages of successful intercourse attempts relative to the total number of intercourse attempts over the 14-day open-label treatment period compared with the 14-day double-blind treatment period by dose group during the double-blind treatment period. A successful attempt was defined by a "yes" response to the sexual encounter profile diary question #3: "Did your erection last long enough for you to have successful intercourse?"
Time frame: 14-day double-blind and 14-day open-label
Sexual Encounter Profile Diary Question 3, Percentages of Yes Responses During the Double-blind Period and the Open-label Period for Participants Who Didn't Respond to Tadalafil 2.5 mg During Double-blind Period
Assessed were percentages of successful intercourse attempts relative to the total number of intercourse attempts in both treatment periods. A successful attempt was defined by a "yes" response to the sexual encounter profile diary question #3: "Did your erection last long enough for you to have successful intercourse?"
Time frame: 14 days double-blind and 14 days open-label
| Milestone | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Started | 121 | 118 | 133 |
| Completed | 111 | 108 | 124 |
| Not completed | 10 | 10 | 9 |
| Withdrew: Adverse event | 1 | 2 | 0 |
| Withdrew: Entry criteria not met | 3 | 2 | 1 |
| Withdrew: Lost to follow-up | 1 | 2 | 1 |
| Withdrew: Physician decision | 1 | 0 | 0 |
| Withdrew: Protocol violation | 3 | 3 | 3 |
| Withdrew: Sponsor decision | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 1 | 1 | 2 |
| Milestone | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Started | 111 | 108 | 124 |
| Completed | 110 | 105 | 122 |
| Not completed | 1 | 3 | 2 |
| Withdrew: Lost to follow-up | 1 | 2 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 2 |
Cumulative percentage of participants achieving successful intercourse, as measured by "yes" responses to Sexual Encounter Profile diary question 3 (SEP3). SEP3 asks if the participant's erection lasted long enough to have successful intercourse.
| cumulative percentage of participants | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| <= day 4 | 54.5 | 62.2 | 47.2 |
| <= day 3 | 49.1 | 55.0 | 42.3 |
| <= day 2 | 42.0 | 48.6 | 36.6 |
| <= day 1 | 28.6 | 25.2 | 28.5 |
Assessed was the mean change from baseline in the percentage of "yes" responses to the Sexual Encounter Profile Diary question number 1: "Were you able to achieve at least some erection (some enlargement of the penis)"? Data are presented as the mean percentage of participants who answered "yes".
| percentage of participants | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Sexual Encounter Profile Diary Question Number 1, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses | 1.97 ± 2.33 | 2.74 ± 2.34 | -10.06 ± 2.24 |
Assessed was the mean change from baseline in the percentage of "yes" responses to the Sexual Encounter Profile Diary question number 2: "Were you able insert your penis into your partner's vagina?" Data are presented as the mean percentage of participants who answered yes.
| percentage of participants | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Sexual Encounter Profile Diary Question Number 2, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses | 8.11 ± 2.55 | 13.12 ± 2.56 | -7.29 ± 2.44 |
Assessed was the mean change from baseline in the percentage of "yes" responses to the Sexual Encounter Profile Diary question number 3: "Did your erection last long enough for you to have successful intercourse?" Data are presented as the mean percentage of participants who answered "yes".
| percentage of participants | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Sexual Encounter Profile Diary Question Number 3, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses | 15.67 ± 2.76 | 21.94 ± 2.77 | 1.40 ± 2.64 |
Assessed was the mean change from baseline in the percentage of "yes" responses to the Sexual Encounter Profile Diary question number 4: "Were you satisfied with the hardness of your erection?" Data are presented as the mean percentage of participants who answered "yes".
| percentage of participants | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Sexual Encounter Profile Diary Question Number 4, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses | 20.94 ± 2.90 | 28.50 ± 2.92 | 6.70 ± 2.77 |
Assessed was the mean change from baseline in the percentage of "yes" responses to the Sexual Encounter Profile Diary question number 5: "Were you satisfied overall with this sexual experience?" Data are presented as the mean percentage of participants who answered "yes".
| percentage of participants | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Sexual Encounter Profile Diary Question Number 5, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses | 20.45 ± 2.82 | 25.60 ± 2.84 | 6.52 ± 2.71 |
Assessed was the median time to onset of efficacy (day when 50% of participants have had at least 1 successful intercourse attempt) within the first 4 days of therapy based on a "yes" response to the sexual encounter profile diary question 3: "Did your erection last long enough for you to have successful intercourse?" Data are based on participants who responded "yes". For the placebo group, onset of efficacy was not reached within the first 4 days of therapy, therefore, the analysis timeframe was expanded for this group to determine the median time to onset of efficacy.
| days | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Sexual Encounter Profile Diary Question 3, the Overall Distribution of Time to Onset by Yes Responses | 4.0 ± 0.878 | 3.0 ± 0.384 | 6.0 ± 2.283 |
Assessed was the cumulative precentage of successful intercourse attempts (successful attempts relative to the total number of intercourse attempts) over the 14-day double-blind treatment period. A successful attempt was defined by a "yes" response to the sexual encounter profile diary question #3: "Did your erection last long enough for you to have successful intercourse?" Data are presented as the proportion of intercourse attempts for which participants answered "yes" relative to the total number of intercourse attempts. Total number of attempts = TNA.
| percentage of total number of attempts | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| <=day14 (TNA: n=905; n=813; n=781) | 45.1 | 46.6 | 30.9 |
| <=day13 (TNA: n=877; n=777; n=755) | 44.5 | 46.2 | 31.2 |
| <=day12 (TNA: n=827; n=730; n=711) | 44.0 | 45.9 | 30.8 |
| <=day11 (TNA: n=774; n=678; n=668) | 43.2 | 44.9 | 30.7 |
| <=day10 (TNA: n=726; n=626; n=625) | 41.9 | 44.2 | 30.6 |
| <=day9 (TNA: n=668; n=574; n=572) | 40.2 | 43.7 | 29.8 |
| <=day8 (TNA: n=608; n=534; n=523) | 39.5 | 42.8 | 29.6 |
| <=day7 (TNA: n=563; n=483; n=481) | 38.7 | 42.4 | 28.8 |
| <=day6 (TNA: n=505; n=439; n=435) | 37.4 | 41.6 | 27.9 |
| <=day5 (TNA: n=464; n=402; n=396) | 36.6 | 41.4 | 27.4 |
| <=day4 (TNA: n=412; n=350; n=352) | 37.1 | 40.9 | 26.2 |
| <=day3 (TNA: n=324; n=265; n=262) | 35.5 | 38.5 | 27.2 |
| <=day2 (TNA: n=214; n=179; n=175) | 35.8 | 38.9 | 28.0 |
| <=day1 (TNA: n=109; n=83; n=83) | 38.6 | 33.7 | 32.1 |
Assessed were percentages of successful intercourse attempts relative to the total number of intercourse attempts over the 14-day open-label treatment period compared with the 14-day double-blind treatment period by dose group during the double-blind treatment period. A successful attempt was defined by a "yes" response to the sexual encounter profile diary question #3: "Did your erection last long enough for you to have successful intercourse?"
| percentage successful attempts | Placebo Double-blind | Tadalafil 5 mg Open-label |
|---|---|---|
| Sexual Encounter Profile Diary Question 3, Percentages of Yes Responses During the Double-blind and Open-label Periods for Participants Who Were Assigned to Placebo in the Double-blind Treatment Period | 32.21 ± 35.35 | 68.27 ± 38.76 |
Assessed were percentages of successful intercourse attempts relative to the total number of intercourse attempts over the 14-day open-label treatment period compared with the 14-day double-blind treatment period by dose group during the double-blind treatment period. A successful attempt was defined by a "yes" response to the sexual encounter profile diary question #3: "Did your erection last long enough for you to have successful intercourse?"
| percentage successful attempts | Tadalafil 2.5 mg Double-blind | Tadalafil 5 mg Open-label |
|---|---|---|
| Sexual Encounter Profile Diary Question 3, Percentages of Yes Responses in the Double-blind Period and the Open-label Period for Participants Who Were Assigned to Tadalafil 2.5 mg in the Double-blind Treatment Period | 46.11 ± 37.17 | 68.33 ± 40.10 |
Assessed were percentages of successful intercourse attempts relative to the total number of intercourse attempts over the 14-day open-label treatment period compared with the 14-day double-blind treatment period by dose group during the double-blind treatment period. A successful attempt was defined by a "yes" response to the sexual encounter profile diary question #3: "Did your erection last long enough for you to have successful intercourse?"
| percentage successful attempts | Tadalafil 5 mg Double-blind | Tadalafil 5 mg Open-label |
|---|---|---|
| Sexual Encounter Profile Diary Question 3, Percentages of Yes Responses in the Double-blind Period and the Open-label Period for Participants Who Were Assigned to Tadalafil 5 mg in the Double-blind Treatment Period | 49.54 ± 38.60 | 67.70 ± 38.98 |
Assessed were percentages of successful intercourse attempts relative to the total number of intercourse attempts in both treatment periods. A successful attempt was defined by a "yes" response to the sexual encounter profile diary question #3: "Did your erection last long enough for you to have successful intercourse?"
| percentage successful attempts | Tadalafil 2.5 mg Double-blind | Tadalafil 5 mg Open-label |
|---|---|---|
| Sexual Encounter Profile Diary Question 3, Percentages of Yes Responses During the Double-blind Period and the Open-label Period for Participants Who Didn't Respond to Tadalafil 2.5 mg During Double-blind Period | 32.51 ± 40.77 | 57.62 ± 45.27 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tadalafil 2.5 mg | — | 0/121 (0%) | 13/121 (10.7%) |
| Tadalafil 5 mg | — | 0/118 (0%) | 12/118 (10.2%) |
| Placebo | — | 0/133 (0%) | 8/133 (6%) |
| Tadalafil 2.5 mg to Tadalafil 5 mg | — | 0/111 (0%) | 6/111 (5.4%) |
| Tadalafil 5 mg to Tadalafil 5 mg | — | 0/108 (0%) | 9/108 (8.3%) |
| Placebo to Tadalafil 5 mg | — | 0/124 (0%) | 4/124 (3.2%) |
| Event | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo | Tadalafil 2.5 mg to Tadalafil 5 mg | Tadalafil 5 mg to Tadalafil 5 mg | Placebo to Tadalafil 5 mg |
|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 1/121 | 1/118 | 0/133 | 3/111 | 1/108 | 1/124 |
| Back painMusculoskeletal and connective tissue disorders | 1/121 | 3/118 | 0/133 | 0/111 | 0/108 | 1/124 |
| Sinus congestionRespiratory, thoracic and mediastinal disorders | 0/121 | 0/118 | 0/133 | 0/111 | 2/108 | 0/124 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/121 | 2/118 | 1/133 | 0/111 | 0/108 | 1/124 |
| Upper respiratory tract infectionInfections and infestations | 2/121 | 0/118 | 0/133 | 1/111 | 0/108 | 0/124 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 0/121 | 0/118 | 2/133 | 0/111 | 0/108 | 0/124 |
| DyspepsiaGastrointestinal disorders | 1/121 | 1/118 | 1/133 | 0/111 | 1/108 | 0/124 |
| Gastrointestinal disorderGastrointestinal disorders | 0/121 | 0/118 | 0/133 | 0/111 | 1/108 | 0/124 |
| CellulitisInfections and infestations | 0/121 | 0/118 | 0/133 | 0/111 | 1/108 | 0/124 |
| Localised infectionInfections and infestations | 0/121 | 0/118 | 0/133 | 0/111 | 1/108 | 0/124 |
| Age Continuous(years) | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 59.63 ± 10.02 | 57.68 ± 11.07 | 59.23 ± 10.63 | 58.87 ± 10.58 |
| Sex: Female, Male(Participants) | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 121 | 118 | 133 | 372 |
| Race/Ethnicity, Customized(participants) | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 4 | 0 | 0 | 4 |
| Asian | 2 | 4 | 1 | 7 |
| Black or African American | 25 | 21 | 22 | 68 |
| Multiple | 1 | 6 | 2 | 9 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 |
| White | 89 | 87 | 107 | 283 |
| Region of Enrollment(participants) | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo | Total |
|---|---|---|---|---|
| United States | 121 | 118 | 133 | 372 |
| Sexual Encounter Profile Diary question number 1(percentage of participants) | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 74.04 ± 35.64 | 75.22 ± 35.69 | 82.26 ± 28.98 | 77.34 ± 33.55 |
| Sexual Encounter Profile Diary question number 2(percentage of participants) | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 52.70 ± 40.58 | 54.20 ± 39.47 | 56.16 ± 37.14 | 54.41 ± 38.94 |
| Sexual Encounter Profile Diary question number 3(percentage of participants) | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 30.90 ± 36.99 | 25.42 ± 32.62 | 29.95 ± 34.85 | 28.80 ± 34.85 |
| Sexual Encounter Profile Diary question number 4(percentage of participants) | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 8.33 ± 19.18 | 4.96 ± 13.19 | 8.36 ± 16.88 | 7.26 ± 16.64 |
1 further baseline measures are reported on the registry.
The record gives a start of Feb 2009, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2010, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tadalafil